Current status of molecular targeted therapy for hematologic malignancies: introduction

ISSN： 1341-9625

Source： International Journal of Clinical Oncology, Vol.19, Iss.1, 2014-02, pp. : 1-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Current status of antivascular therapy and targeted treatment in the clinic

By Dahl Olav Borkamo Erling Dahl Fluge Øystein

International Journal of Hyperthermia, Vol. 24, Iss. 1, 2008-02 ,pp. : 97-110

Informa Healthcare

Access to resources Recommend Favorite

Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies

By Karp Judith E Lancet Jeffrey E

Future Oncology, Vol. 1, Iss. 6, 2005-12 ,pp. : 719-731

Future Medicine

Access to resources Recommend Favorite

HEMATOLOGIC MALIGNANCIES

Cancer Investigation, Vol. 25, Iss. 1, 2007-01 ,pp. : 33-47

Informa Healthcare

Access to resources Recommend Favorite

Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science

By Tanaka Shinji Arii Shigeki

International Journal of Clinical Oncology, Vol. 15, Iss. 3, 2010-06 ,pp. : 235-241

Springer Publishing Company

Access to resources Recommend Favorite

Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice

By Kudo Masatoshi

International Journal of Clinical Oncology, Vol. 15, Iss. 3, 2010-06 ,pp. : 242-255

Springer Publishing Company

Access to resources Recommend Favorite